First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis
Current Oncology · 04.03.2025 · 32 (3) · 148
DOI: 10.3390/curroncol32030148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 04.03.2025. Verfasst von Yan Xiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Acrylamides, Lung Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study is supported by the National Natural Science Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
HER2 mutations are rare driver events in advanced NSCLC, with limited relief from current targeted therapies. This study aimed to characterize the molecular features of HER2-mutant NSCLC and to evaluate the clinical efficacy of pyrotinib-based combination therapy as a first-line treatment, providing evidence for optimizing treatment strategies.
Methods
NSCLC patients diagnosed at Jiangsu Province People’s Hospital from 2016 to 2024 were enrolled. HER2-positive cases were screened by IHC/FISH and further profiled by NGS. Treatment response was assessed by RECIST 1.1, and survival analysis was performed using Kaplan–Meier and log-rank tests.
Results
Among 144 HER2-mutant NSCLC cases confirmed by NGS, 10 insertion mutations, 26 missense mutations, and 2 fusion mutations were identified. The most common mutation was the exon 20 p.A775_G776insYVMA (47.9%), and TP53 was the most frequent co-mutation (10.4%). In terms of efficacy, the pyrotinib-based combination therapy demonstrated significant clinical benefit, with an ORR of 33.3%, DCR of 95.2%, median PFS (mPFS) of 11.3 months (95% CI: 10.27–12.26), and median OS (mOS) of 21.0 months (95% CI: 18.00–23.94). Subgroup analysis revealed no significant impact of mutation subtype or co-mutation status on the treatment efficacy, but patients with brain metastases had a significantly worse prognosis than those without metastasis (mPFS: 5.1 vs. 12.9 months, p < 0.01; mOS: 9.3 vs. 26.5 months, p < 0.01). All TRAEs were grade 1–3 (any grade: 90.5%; grade 3: 14.3%), with the most common TRAE being diarrhea (any grade: 85.7%; grade 3: 9.5%).
Conclusions
Pyrotinib-based combination therapy is a feasible first-line treatment for HER2-mutant NSCLC, demonstrating significant survival benefits and manageable toxicity. However, brain metastasis patients require enhanced comprehensive management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
ORCID-Profile: Yan Xiang
Förderung
- This study is supported by the National Natural Science Foundation of China
- National Natural Science Foundation of China
Zitieren
APA
Xiang, Y., Zhang, M., Wang, Q., Liu, J., Zeng, L., Sun, A., & Lu, K. (2025). First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis. Current Oncology, 32(3), 148. https://doi.org/10.3390/curroncol32030148
Vancouver
Xiang Y, Zhang M, Wang Q, Liu J, Zeng L, Sun A, et al. First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis. Current Oncology. 2025;32(3):148. doi:10.3390/curroncol32030148
BibTeX
@article{Xiang2025,
author = {Xiang, Yan and Zhang, Meiling and Wang, Qian and Liu, Jingwen and Zeng, Lulin and Sun, Ao and Lu, Kaihua},
title = {First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis},
journal = {Current Oncology},
year = {2025},
volume = {32},
number = {3},
pages = {148},
doi = {10.3390/curroncol32030148}
}
EUVIMED